The researchers, led by Caoimhe Morley and Christos Proukakis, built on their earlier finding that somatic copy number gains of SNCA, the gene encoding alpha-synuclein, occur in the brains of people with synucleinopathies. In their new study, published in Acta Neuropathologica, they asked whether these gains arise specifically in oligodendrocytes, whether they cluster in the brain regions most damaged by the disease, and whether they correlate with the pathological inclusions that define it. Their strategy hinged on a technically demanding hybrid method that combines fluorescent in situ hybridisation, or FISH, with immunofluorescence, applied not to tissue sections but to suspensions of individual nuclei isolated from fresh-frozen post-mortem brain tissue.

The methodological choice matters. Working on sections makes it nearly impossible to reliably detect copy number losses, because slicing the tissue can truncate FISH signals and mimic a missing gene copy. Isolating nuclei eliminates this artefact while preserving alpha-synuclein inclusions, which in multiple system atrophy often sit in perinuclear or nuclear positions and remain attached to the nuclei during preparation. Each nucleus could therefore be interrogated on several axes simultaneously: the number of SNCA copies it carried, whether it belonged to the oligodendrocyte lineage as marked by the transcription factor SOX10, and whether it harboured an alpha-synuclein inclusion. The team analysed tissue from the putamen, cerebellum and substantia nigra of 13 cases with the striatonigral degeneration subtype, 12 cases with the olivopontocerebellar atrophy subtype, and 15 controls from the Queen Square Brain Bank.

The results were striking. Somatic SNCA copy number variants, both gains and losses, were significantly more frequent in multiple system atrophy oligodendrocytes than in controls. Gains were enriched more than threefold, appearing in 6.3 percent of SOX10-positive oligodendrocytes compared with 2.0 percent in controls, while losses were present in 12.5 percent versus 7.4 percent, with both differences highly significant. Crucially, the gains were not randomly distributed. They concentrated in the regions preferentially devastated by each disease subtype: the putamen in striatonigral degeneration and the cerebellum in olivopontocerebellar atrophy, along with the substantia nigra in both. The analysis also showed that CNVs were preferentially enriched at the SNCA locus itself; a chromosome 7 reference probe displayed relative genomic stability, indicating a locus-specific phenomenon rather than wholesale genomic chaos.

The single-cell correlations provide the study’s most provocative evidence. In the preferentially affected region of each subtype, oligodendrocytes carrying a somatic SNCA gain were more than twice as likely to contain an alpha-synuclein inclusion as their neighbours with a normal copy number, an effect that vanished in less affected regions. At the regional level, the frequency of oligodendrocyte gains correlated significantly with the overall burden of glial inclusions. This dovetails with established biology: people who inherit extra copies of SNCA develop parkinsonism driven by chronic alpha-synuclein overproduction, with duplications causing later-onset disease and triplications causing aggressive early-onset forms. Mouse models engineered to overexpress human alpha-synuclein specifically in oligodendrocytes develop inclusion-like pathology, demyelination and neuroinflammation. The new data suggest that the same dosage logic operates cell by cell in the human disease brain, with gains locally pushing intracellular alpha-synuclein toward the aggregation threshold.

Perhaps the most clinically resonant finding is a correlation between copy number gain burden and disease onset. Cases carrying a higher average proportion of oligodendrocyte SNCA gains developed symptoms significantly earlier, with a Spearman correlation coefficient of minus 0.45 and a p-value of 0.03. No such relationship existed for gains in non-oligodendroglial cells or for losses. Moreover, within individual cases, the level of gains correlated across brain regions and between oligodendrocytes and other cell populations, hinting that some patients carry an intrinsic, case-wide propensity for SNCA mosaicism. This raises the possibility of an early clonal event, arising during development, that seeds descendant cells across multiple regions and predisposes the brain to alpha-synuclein aggregation decades later. Distinguishing this from a generalised susceptibility to SNCA instability will require deep single-cell whole-genome sequencing, which is only now approaching the necessary resolution.

The study also reported, for the first time in multiple system atrophy, somatic SNCA losses. These were elevated in both oligodendrocytes and other cells but told a different story. They showed no clear regional predilection matching each subtype’s pathology, associated with inclusions only in the substantia nigra, and showed no correlation with age of onset or disease duration. That pattern argues against a primary causal role. Unlike gains, germline losses of SNCA have never been linked to synucleinopathies, and mice lacking alpha-synuclein do not develop relevant neurodegenerative phenotypes. The authors instead propose that losses may arise secondarily as the disease progresses, through the mis-repair of DNA damage.

That hypothesis gains weight from the study’s final arm, an examination of DNA double-strand breaks using immunofluorescence for gamma H2AX, the phosphorylated histone that marks sites of breakage and repair. Across the sampled regions, the proportion of gamma H2AX-positive cells was significantly higher in multiple system atrophy than in controls, 4.9 versus 2.5 percent overall, and nearly fourfold higher within oligodendrocytes. The signal was stronger in the preferentially affected regions and, strikingly, present in 22.2 percent of inclusion-bearing cells versus 14.9 percent of inclusion-free ones. This mirrors recent reports in Lewy body diseases linking DNA damage to alpha-synuclein pathology. Because post-mitotic brain cells repair double-strand breaks through the error-prone non-homologous end joining pathway, unrepaired or mis-repaired breaks can generate deletions, potentially including SNCA itself. Yet the authors caution that more than three-quarters of inclusion-positive cells showed no evidence of breaks, and the temporal sequence of damage, aggregation and copy number change remains unresolved.

The findings do not paint copy number variation as a sole cause. Most inclusion-bearing oligodendrocytes carried a normal SNCA copy number, and individuals with inherited SNCA multiplications typically develop a Parkinson-like picture rather than full multiple system atrophy, suggesting that somatic gains act as one influential contributor among many, a first hit or modifier that lowers the threshold for aggregation within vulnerable glia. Cell-type-specific stress, environmental exposures, unidentified inherited variants and other somatic mutations, possibly including age-related clonal haematopoiesis recently associated with the disease, are likely to complete the picture. Even so, the work reframes the search for multiple system atrophy’s origins. The culprit may not lie in the genome everyone inherits, but in the mosaic of genomes that individual brain cells acquire across a lifetime, and in oligodendrocytes silently accumulating extra copies of the very gene whose protein will one day fill them with inclusions.

Subject of Research: Somatic SNCA copy number variation in oligodendrocytes and its role in multiple system atrophy pathogenesis

Article Title: Oligodendroglial somatic SNCA copy number gains are associated with inclusions and disease onset in multiple system atrophy

Article References: Oligodendroglial somatic SNCA copy number gains are associated with inclusions and disease onset in multiple system atrophy. (n.d.). https://doi.org/10.1007/s00401-026-03077-4

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03077-4

Keywords: multiple system atrophy, SNCA, alpha-synuclein, oligodendrocytes, somatic copy number variants, glial cytoplasmic inclusions, DNA double-strand breaks, gamma H2AX, fluorescent in situ hybridisation, genetic mosaicism, synucleinopathy, neurodegeneration

Historically, the detection of large-scale mosaic somatic CNVs in the human brain has been fraught with technical challenges and conflicting evidence. Early clonal analyses using fetal human brain tissues revealed minimal large-scale CNV presence at the single-cell level, suggesting that significant somatic genomic variation might not arise early in development. However, contrasting data emerged from single-cell whole-genome amplification (snWGA) on postmortem adult brain samples, revealing that between 13% and 41% of frontal cortical neurons could harbor at least one megabase-scale de novo CNV. This discrepancy suggests that many somatic genomic changes might accumulate during later neurodevelopmental stages, highlighting temporally dynamic mutagenesis in brain cells postnatally.

These megabase-scale CNVs encompass substantial segments of chromosomes, often resulting in dramatic alterations in gene dosage, which may influence neuronal identity and function. Strikingly, certain CNVs map onto regions implicated in neuropsychiatric disorders, such as duplications at chromosome 15q13.2-13.3. This locus is recurrently duplicated in conditions manifesting cognitive and behavioral phenotypes, hinting that somatic CNVs might contribute to pathology by generating genetic heterogeneity within the brain’s neuronal population. These findings encourage a reevaluation of traditional monogenic models of neurological diseases, suggesting a mosaic genomic underpinning that modulates neural circuit function on a microscopic scale.

A crucial driver of this somatic genomic variability involves the activity of mobile genetic elements, particularly retrotransposons such as Long Interspersed Nuclear Element 1 (LINE-1 or L1). These retrotransposons possess intrinsic enzymatic machinery enabling their transcription, reverse transcription, and insertion into new genomic loci. This capacity for mobilization makes L1 retrotransposons a potent source of mutagenic variation, dynamically reshaping neuronal genomes. During neural progenitor proliferation, L1 activity has been demonstrated to alter gene expression patterns and influence neuronal maturation, suggesting a developmental window during which these elements impact brain architecture and function fundamentally.

At the molecular level, retrotransposons form RNA-protein complexes with reverse transcriptase activity. Upon transcription, they produce complementary DNA that integrates elsewhere in the genome, introducing insertional mutations and additional copy number variability. While this insertional mutagenesis could disrupt coding or regulatory sequences crucial for neuronal function, the full spectrum of L1-induced genomic alterations remains under active investigation. These mobile elements may serve paradoxical roles; while contributing mutational burden, they also promote genomic plasticity that could underlie adaptive processes during neurodevelopment.

Beyond mere insertional events, L1 retrotransposons can induce DNA damage, notably double-strand breaks (DSBs), which represent severe genomic lesions. Experimental evidence from cancer cell studies has confirmed that L1 mobilization correlates with increased DNA damage and apoptosis, mechanistically implicating these elements in genome destabilization. Given that neuronal populations show high rates of somatic CNVs and L1 activity, it is plausible that retrotransposon-induced DNA damage may trigger repair mechanisms leading to deletions, duplications, or complex rearrangements contributing to neuronal mosaicism.

Intriguingly, direct causative links between L1 retrotransposition and somatic CNV formation in neurons remain unproven, highlighting a critical gap. Whether L1-induced DSBs precipitate the chromosomal rearrangements observed in somatic neurons or whether other mutagenic processes prevail requires further elucidation. Cutting-edge single-cell genomic technologies and longitudinal analyses might shed light on how retrotransposons integrate with DNA repair pathways to influence somatic variability.

Emerging evidence also underscores the environment’s capacity to modulate retrotransposon activity in the brain. In murine models, increased maternal care during early life was associated with significant suppression of L1 retrotransposon accumulation. This suggests that epigenetic and environmental signals can shape genomic mosaicism by dampening or enhancing mobile element activity. Such environmental modulation opens fascinating avenues regarding how early life experiences impact individual neuronal genome architecture and, in turn, cognitive and behavioral outcomes.

The realization that brain cells harbor a dynamic and individualized genomic mosaic adds a new layer of complexity to neuroscience. It challenges the classical notion of neuronal uniformity, proposing instead that each neuron may bear a unique genomic signature with functional consequences. This mosaicism could influence synaptic variability, network properties, and susceptibility to neuropsychiatric disorders, offering a potential mechanistic basis linking genetics with phenotypic diversity in brain function and disease manifestation.

Understanding the interplay between somatic CNVs, mobile element activity, and neuronal function has profound therapeutic implications. Targeting retrotransposon mobilization pathways or modulating DNA damage responses might mitigate deleterious genomic variability. Moreover, interventions aimed at early environmental enhancement could offer non-pharmacological routes to stabilize neuronal genomes, highlighting a fascinating intersection between genetics, epigenetics, and lived experience.

Technological advances have been pivotal in unraveling somatic mosaicism in the brain. Single-cell sequencing platforms and sensitive whole-genome amplification methods have provided snapshots of neuronal genome diversity at unprecedented resolution. As these techniques evolve, enabling more comprehensive and precise maps of mosaicism, researchers anticipate uncovering the full extent to which somatic genomic variation contributes to brain development, plasticity, and disease.

The field now faces significant challenges, including distinguishing genuine somatic mutations from technical artifacts and understanding the functional consequences of mosaicism at the systems level. Integrating genomic data with transcriptomic, epigenomic, and electrophysiological profiles will be essential to translate genomic mosaicism into biological and clinical insights. Furthermore, elucidating whether somatic mutations act independently or interactively within neuronal circuits remains a critical frontier.

Future research will likely expand into exploring somatic mosaicism beyond neurons, including glial populations, which also influence brain homeostasis and pathology. Understanding how somatic variation in diverse brain cell types contributes to disease susceptibility and progression could revolutionize neurobiology and open new therapeutic vistas tailored to the mosaic brain.

In sum, the increasing recognition of somatic mosaicism in the human brain reframes our understanding of neurological disease etiology and neurodevelopmental biology. The confluence of genomic instability, retrotransposon activity, and environmental modulation underscores a complex genetic ecosystem within the brain. As experimental methodologies mature and conceptual frameworks shift, the prospect of decoding the brain’s somatic genomic mosaic promises to transform neuroscience into a more nuanced and precise science.

This burgeoning field eloquently illustrates how genome dynamics sculpt neural identity and function, challenging the deterministic view of genetics in the nervous system. By integrating somatic variability into models of brain health and disease, researchers move closer to unraveling the mysteries of cognition, consciousness, and neurodegeneration, heralding a new era in personalized neurology.

Subject of Research: Brain somatic mosaicism, somatic copy number variants (CNVs), retrotransposons, neuronal genomic variation, and their roles in neurodevelopment and disease.

Article Title: Disease insights from brain somatic mosaicism.

Article References:
Chung, C., Nedunuri, R. & Gleeson, J.G. Disease insights from brain somatic mosaicism. Exp Mol Med (2026). https://doi.org/10.1038/s12276-024-01331-x

Image Credits: AI Generated

DOI: 08 April 2026